Outlook Therapeutics (OTLK) investor relations material

Executive summary

• LYTENAVA (bevacizumab gamma) launched commercially in Germany and the UK in June 2025, with unit sales more than doubling quarter-over-quarter following launches in Germany, the UK, and Austria.

• Additional European launches are planned for Ireland and the Netherlands in 2026, and France, Italy, and Spain in 2027, with ongoing partnership discussions in other regions.

• The company is seeking FDA approval for ONS-5010/LYTENAVA in the US but received a third Complete Response Letter (CRL) in December 2025, with the FDA requesting additional confirmatory efficacy data; a Type A meeting request was submitted to address this.

• Net loss for the quarter ended December 31, 2025 was $23.1 million, compared to net income of $17.4 million in the prior year period.

• There is substantial doubt about the company's ability to continue as a going concern due to insufficient cash to fund operations for the next year.

Financial highlights

• Revenues, net for the quarter were negative $1.2 million, primarily due to a $1.1 million increase in returns reserve from lower-than-forecasted sell-through in the UK and administrative fees.

• Research and development expenses decreased to $3.6 million from $9.7 million year-over-year, mainly due to lower clinical trial costs.

• Selling, general and administrative expenses decreased to $8.6 million from $11.9 million, reflecting lower compensation and professional fees, partially offset by higher Europe launch expenses.

• Net cash used in operating activities was $14.9 million; net cash provided by financing activities was $15.5 million, mainly from ATM equity sales.

• Cash and cash equivalents stood at $8.7 million as of December 31, 2025, excluding $2.4 million in net proceeds from an at-the-market offering received after quarter-end.

Outlook and guidance

• Additional financing is required to fund operations and commercialization efforts; management is evaluating licensing, partnerships, debt, and equity options.

• Continued commercial expansion in Europe is expected, with launches in additional EU countries and ongoing efforts to secure partnerships in other global markets.

• The company plans to focus on working with the FDA for a regulatory pathway and preparing for a potential US launch if approved.